Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chime Biologics of Wuhan BioLake Separates its CDMO Operations from JHL Biotech

publication date: Apr 16, 2020

Chime Biologics of Wuhan announced it has completed its separation from Taiwan's JHL Biotech, spinning out the CDMO operations into the new company. In 2019, JHL settled an IP suit brought by Genentech by agreeing to stop development of four Genentech biosimilars. Chime's state-of-the-art 150,000 square feet facility, located in Wuhan BioLake, currently has five bioreactors with 9,000 L of total capacity. The company wants to become one of the largest CDMO providers in China by expanding capacity to 27,000 L by 2022 and 140,000+ L by 2024. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital